Cure8 research brief
Finding reliable blood biomarkers for ulcerative colitis activity could make monitoring disease flares easier and less dependent on invasive tests. NGAL and S100A12 rising with active disease suggests they might help detect flares or track response.
Clinicians, researchers working on IBD biomarkers, and adults with ulcerative colitis interested in noninvasive monitoring
The report measured serum NGAL and S100A12 in the same patients during active disease and remission, plus a healthy control group. Both markers were higher during active UC and showed good discrimination by ROC analysis according to the abstract. The study appears to be a clinical observational study with matched within-patient comparisons.
This summary is based on the article abstract (partial extraction). The abstract reports higher serum NGAL and S100A12 in active UC and ROC discrimination but does not include full methodological or validation details; consult the full paper before drawing clinical conclusions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
A blood biomarker that rises with active ulcerative colitis could help patients and clinicians monitor disease activity without relying solely on invasive tests. This study reports that serum type 23 collagen ectodomain...
